title: Review of UV spectroscopic, chromatographic, and electrophoretic methods for the cholinesterase reactivating antidote pralidoxime (2-PAM).
abstract: Pralidoxime (2-PAM) belongs to the class of monopyridinium oximes with reactivating potency on cholinesterases inhibited by phosphylating organophosphorus compounds (OPC), for example, pesticides and nerve agents. 2-PAM represents an established antidote for the therapy of anticholinesterase poisoning since the late 1950s. Quite high therapeutic concentrations in human plasma (about 13 µg/ml) lead to concentrations in urine being about 100 times higher allowing the use of less sensitive analytical techniques that were used especially in the early years after 2-PAM was introduced. In this time (mid-1950s until the end of the 1970s) 2-PAM was most often analyzed by either paper chromatography or simple UV spectroscopic techniques omitting any sample separation step. These methods were displaced completely after the establishment of column liquid chromatography in the early 1980s. Since then, diverse techniques including cation exchange, size-exclusion, reversed-phase, and ligand-exchange chromatography have been introduced. Today, the most popular method for 2-PAM quantification is ion pair chromatography often combined with UV detection representing more than 50% of all column chromatographic procedures published. Furthermore, electrophoretic approaches by paper and capillary zone electrophoresis have been successfully used but are seldom applied. This review provides a commentary and exhaustive summary of analytical techniques applied to detect 2-PAM in pharmaceutical formulations and biological samples to characterize stability and pharmacokinetics as well as decomposition and biotransformation products. Separation techniques as well as diverse detectors are discussed in appropriate detail allowing comparison of individual preferences and limitations. In addition, novel data on mass spectrometric fragmentation of 2-PAM are provided.
authors.affiliation: Bundeswehr Institute of Pharmacology andToxicology; Neuherbergstrasse 11, Munich, Germany. HaraldJohn@bundeswehr.org
authors.forename: Harald
authors.initials: H
authors.lastname: John
authors.forename: Marc-Michael
authors.initials: MM
authors.lastname: Blum
mesh_terms: D000818:Animals; D000931:Antidotes / Q000032:analysis* / Q000493:pharmacokinetics* / Q000494:pharmacology / Q000627:therapeutic use; D002801:Cholinesterase Reactivators / Q000032:analysis* / Q000493:pharmacokinetics* / Q000494:pharmacology / Q000627:therapeutic use; D002845:Chromatography / Q000379:methods; D004586:Electrophoresis / Q000379:methods; D006801:Humans; D009682:Magnetic Resonance Spectroscopy / Q000379:methods; D004364:Pharmaceutical Preparations / Q000737:chemistry; D011220:Pralidoxime Compounds / Q000032:analysis* / Q000493:pharmacokinetics* / Q000494:pharmacology / Q000627:therapeutic use; D013055:Spectrophotometry, Infrared / Q000379:methods; D013056:Spectrophotometry, Ultraviolet / Q000379:methods
chemical_list: D000931:Antidotes; D002801:Cholinesterase Reactivators; D004364:Pharmaceutical Preparations; D011220:Pralidoxime Compounds; C028797:pralidoxime